[\textsuperscript{68}Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma

Jolanta Kunikowska\textsuperscript{1}• Bartosz Cieślak\textsuperscript{2}• Beata Gieriej\textsuperscript{3}• Waldemar Patkowski\textsuperscript{4}• Leszek Kraj\textsuperscript{5,6}• Marcin Kotulski\textsuperscript{4}• Krzysztof Zieniewicz\textsuperscript{4}• Leszek Królicki\textsuperscript{1}

Received: 17 May 2020 / Accepted: 27 August 2020 / Published online: 3 September 2020

Abstract

**Purpose** Prostate-specific membrane antigen (PSMA) is not only highly expressed on the surface prostate cancer cells but is also elevated during angiogenesis in other cancer cell types, including hepatocellular carcinoma (HCC). This study aimed to evaluate the feasibility of using PET/CT imaging with [\textsuperscript{68}Ga]Ga-PSMA-11 in HCC and its impact on patient management.

**Methods** Fifteen patients (13 men and two women; aged 55.6 ± 18.2 years) with HCC were enrolled in this prospective, single-institution study. All patients underwent contrast-enhanced MRI/CT, [\textsuperscript{68}Ga]Ga-PSMA-11 PET/CT, and histopathological verification of lesions.

**Results** No radiopharmaceutical-related adverse events were noted. Visual interpretation showed increased accumulation of [\textsuperscript{68}Ga]Ga-PSMA-11 in all HCC patients. The tumor-to-liver ratio (TLR) was 3.6 ± 2.1, and the maximal standardized uptake value (SUV\textsubscript{max}) was 13.5 ± 7.1. There were no significant differences in the SUVs or TLR between newly diagnosed and recurrent patients. No statistically significant relationship was found between serum concentration of tumor markers (i.e., AFP, CA 19-9, CEA) and PET parameters. Results of the [\textsuperscript{68}Ga]Ga-PSMA-11 PET/CT changed the treatment strategy in five (33%) patients. PSMA staining showed visible heterogeneity in terms of intensity and distribution: the reaction was weak and only observed in a few vessels in pseudoglandular patterns of HCC, while it was homogeneously strong, with some hot spots, in trabecular patterns of HCC.

**Conclusion** [\textsuperscript{68}Ga]Ga-PSMA-11 PET/CT can detect PSMA expression in vivo in patients with HCC and is useful for guiding treatment strategies. Further investigation of the clinical utility of this method in HCC is warranted.

**Keywords** PSMA • HCC • [\textsuperscript{68}Ga]Ga-PSMA-11 • Hepatocellular carcinoma

Introduction

Hepatocellular carcinoma (HCC) is the most common type of primary liver malignancy, and the fourth leading cause of cancer-related deaths worldwide [1]. The diagnosis of HCC is challenging and is based on invasive (tumor biopsy) or noninvasive methods (imaging techniques). Due to the difficulties associated with a biopsy (e.g., risk of bleeding, difficulty in targeting the tumor, or cancer cells seeding), imaging techniques have become the preferred way to confirm the diagnosis of HCC. Magnetic resonance imaging (MRI) and computed tomography (CT) are the most commonly used imaging modalities for the radiological diagnosis of HCC; however, their sensitivity is suboptimal, reaching approximately 70% for CT and 80% for MRI [2]. The assessment of HCC recurrence after primary treatment is even more difficult, because of post-therapy changes.
Another imaging option is positron emission tomography (PET) with fluorodeoxyglucose (\(^{18}\text{F}\))FDG), which is widely used in various types of oncological diseases. However, as liver gluconeogenesis in well-differentiated HCC is comparable to normal, the sensitivity of \(^{18}\text{F}\)FDG PET for detecting HCC is not better than that of conventional imaging (50–70%) [2]. Therefore, other PET tracers based on lipid metabolism have been proposed for the detection of HCC, including \(^{11}\text{C}\)C-labeled acetate and \(^{18}\text{F}\)F-choline. \(^{11}\text{C}\)C-labeled acetate reportedly has improved sensitivity for low- and intermediate-grade HCC [3, 2]. Similarly, \(^{18}\text{F}\)F-choline (which is a component of phosphatidylcholine, an essential element in cell membranes) has a similar sensitivity to \(^{11}\text{C}\)C-labeled acetate, ranging from 75 to 87% [3, 2]. Moreover, prostate-specific membrane antigen (PSMA) has been implicated as a potential target for imaging studies in several tumor types.

PSMA, or glutamate carboxypeptidase II, was originally found to be specifically expressed in the epithelial cells of prostate cancer cells. However, recent studies have shown PSMA is also involved in angiogenesis in other cancer types, such as glioblastoma, gastric cancer, colon cancer, bladder cancer, HCC, clear cell renal carcinoma, breast cancer, ovarian cancer, melanoma, and mesothelioma [4–6]. As PSMA is only detected in histopathology during angiogenesis and not on normal vessels, it not only represents a potential novel target for diagnosis but also for therapy [7]. Milowsky et al. first demonstrated PSMA is a valid neovascular target in humans for treating advanced solid tumors by using an \(^{111}\text{Indium}\)-labeled monoclonal antibody (mAb) against PSMA (J591) [8]. Since then, a variety of PSMA-targeted radiotracers have become available, which have potential diagnostic and therapeutic applications [9, 10]. Among them, \(^{68}\text{Ga}\)Ga-PSMA-HBED-CC (PSMA-11), \(^{18}\text{F}\)DCFPyL, and \(^{18}\text{F}\)PSMA-1007 are currently the most commonly used [9].

Since PSMA expression is associated with poor prognosis, the results of \(^{68}\text{Ga}\)Ga-PSMA PET/CT have strong clinical implications [11]. However, to date, the use of \(^{68}\text{Ga}\)Ga-PSMA PET/CT (mainly PSMA-11) for the diagnosis of HCC has only been reported in two studies [12, 13] and several case reports [14–18]. Therefore, this study aimed to evaluate the feasibility of PET/CT imaging with \(^{68}\text{Ga}\)Ga-PSMA-11 in HCC and its impact on patient management.

**Patients and methods**

**Patients**

A total of 15 patients (13 men and two women, mean age 55.6 ± 18.2 years) were qualified for the study. All patients had a diagnosis of HCC confirmed histologically. Among them, ten patients were newly diagnosed; four patients had recurrence after transarterial chemoembolization (TACE); and one patient after hemihepatectomy and TACE. On the basis of Child-Pugh classification and Eastern Cooperative Oncology Group (ECOG) performance status score, 14 were Child-Pugh A/ECOG 0 or 1, and only one participant was Child-Pugh B and ECOG 2. The clinical characteristics of the patients are summarized in Table 1.

### Table 1 The clinical characteristics of the patients

| Number | Sex | Age | History            | AFP (ng/ml N < 7) | CEA (ng/ml N < 3) | CA 19-9 (IU/ml N < 34) | HBV | HCV | Fatty liver | Liver cirrhosis | Child-Pugh | ECOG |
|--------|-----|-----|--------------------|------------------|------------------|-----------------------|-----|-----|-------------|-----------------|------------|------|
| 1      | M   | 72  | Newly diagnosed    | N                | N                | N                     | -   | -   | -           | -               | A          | 0    |
| 2      | F   | 59  | Newly diagnosed    | N                | 13.6             | 66.4                  | -   | +   | +           | +               | A          | 0    |
| 3      | M   | 73  | Newly diagnosed    | 31,158           | N                | N                     | -   | -   | -           | -               | A          | 1    |
| 4      | M   | 64  | Newly diagnosed    | 78.4             | 10.6             | N                     | -   | +   | -           | +               | A          | 1    |
| 5      | M   | 69  | After TACE         | N                | N                | N                     | +   | -   | -           | -               | A          | 1    |
| 6      | M   | 72  | Newly diagnosed    | N                | N                | N                     | -   | -   | +           | -               | A          | 1    |
| 7      | M   | 61  | After TACE         | 5433             | 15.2             | N                     | +   | +   | -           | -               | A          | 0    |
| 8      | M   | 28  | After TACE         | 49.2             | N                | N                     | +   | +   | -           | -               | A          | 1    |
| 9      | F   | 46  | Newly diagnosed    | N                | N                | 51                    | -   | -   | -           | -               | A          | 0    |
| 10     | M   | 66  | Newly diagnosed    | 5738             | N                | N                     | +   | -   | -           | -               | A          | 1    |
| 11     | M   | 53  | Newly diagnosed    | 23.6             | N                | N                     | -   | -   | -           | -               | A          | 0    |
| 12     | M   | 54  | Newly diagnosed    | N                | N                | N                     | +   | -   | +           | +               | A          | 1    |
| 13     | M   | 18  | After TACE         | N                | N                | N                     | -   | -   | -           | -               | A          | 1    |
| 14     | M   | 65  | Newly diagnosed    | 50.2             | 5.2              | 40                    | -   | -   | +           | B               | 2          |      |
| 15     | M   | 71  | After TACE         | 69,533           | N                | N                     | -   | -   | +           | -               | A          | 1    |

**AFP, α-fetoprotein; HCV, hepatitis C virus; HBV, hepatitis B virus; CEA, carcinoembryonic antigen; TACE, transarterial chemoembolization; ECOG, Eastern Cooperative Oncology Group performance status**
Included patients had one or more measurable target lesions (newly diagnosed or previously treated with TACE) based on Response Evaluation Criteria in Solid Tumors (RECIST). Within a 4-week interval, contrast-enhanced CT/MRI (ceCT/MRI) and $[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 PET/CT were performed. Serum concentration of alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA 19-9), and carcinoembryonic antigen (CEA) were assessed before $[^{68}\text{Ga}]^\text{Ga}$-Ga-PSMA-11 PET/CT.

Written informed consent was obtained from all patients before enrolment in the study. The study was approved by the Ethical Committee of Medical University of Warsaw (KB/2/A/2018).

$[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 PET/CT protocol and image interpretation

Radiopharmaceutical preparation of $[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 and the imaging protocol was performed as previously described [5]. Briefly, PET/CT was performed from the skull to the thighs (3 min per bed position, three iterations, 21 subsets) on a Biograph 64 TruePoint (Siemens Medical Solutions Inc., USA) for 60 min post-injection of $[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 (dose of 2 MBq/kg body weight). Image analyses were performed using the Siemens Workstation (Syngovia, MMWS, Siemens Medical Solutions Inc., USA).

On visual evaluation of lesions located in the liver, an uptake of $[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 higher than that of the background liver was considered a positive result. In addition, “minor uptake” was defined as an uptake lower than that of the liver, “moderate uptake,” as a comparable or slightly higher than that of the liver, and “intense uptake” as significantly higher than that of the liver.

For quantitative analysis, the maximal standard uptake value ($\text{SUV}_{\text{max}}$) and mean standard uptake value ($\text{SUV}_{\text{mean}}$) of a positive lesion were measured on $[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 PET/CT images with spherical volumes of interest (VOIs). Tumor-to-liver ratios (TLR) were calculated using the SUVmax of the lesion divided by the SUVmean of the normal liver.

Immunohistochemistry and PSMA evaluation

Tissue pieces obtained during surgery or core needle biopsy were cut into 4-μm sections from paraffin blocks and placed on glass slides. Next, the sections underwent deparaffinization with xylene and dehydration with gradient alcohol. Subsequently, antigen retrieval was performed at high temperature and pressure conditions in pH 9.0 citrate buffer. Sections were incubated with primary PSMA antibody (mouse mAb, Dako/Agilent, Clone 3E6; dilution 1:50). A prostate cancer sample was used as a positive control. The EnVision FLEX was used for the visualization of staining. All sections were then counterstained with hematoxylin. All procedures were performed according to the manufacturer’s instructions.

Vascular PSMA expression was semiquantitatively scored based on staining intensity (weak vs. strong) and distribution. Lesions with no detectable PSMA expression were scored as “0” (negative); lesions with PSMA staining in 1–50% of vascularatures were scored as “1” (low PSMA expression); and lesions with PSMA staining in >50% of vascularatures were scored as “2” (high PSMA expression). Endothelial expression of PSMA in the tumor vasculature was confirmed by CD31 staining, a well-established endothelial cell marker.

The evaluation of immunohistochemical staining was carried out by two experienced pathologists, who were blinded to clinical data.

Statistical methods

All variables were evaluated for their distribution pattern. Means and standard deviations were used to summarize the patients’ characteristics. Calculations were done on Excel for MAC (version 16.28, 2019 Microsoft). The McNemar test of correlated properties was used to compare the results of $[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 and ceCT/MRI imaging. In all cases, a $p$ value < 0.05 was considered statistically significant.

All statistical analysis was performed using GraphPad Prism 5 (GraphPad Software Inc.) software.

Results

Toxicity reporting

No adverse events related to the use of the diagnostic radiopharmaceutical were recorded.

Visual and semiquantitative $[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 PET/CT image analysis

Forty-four lesions in 15 patients demonstrated an uptake in $[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 PET/CT on visual evaluation. Among them, 38 lesions were located in the liver, five in the bones, and one in the peritoneum. Based on visual analysis, intense uptake of $[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 was shown in 30 lesions, with moderate uptake in 11 lesions. Only three bone lesions in the ribs showed a minor uptake of $[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 with an $\text{SUV}_{\text{max}}$ of 2.2–2.4, which was lower than that observed in the liver.

The lesions were also assessed quantitatively using SUVmax, SUVmean, and TLR (as summarized in Table 2). The SUVmax was 13.5 ± 7.1 (range: 2.2–29.3) and the SUVmean was 6.5 ± 2.6 (range: 2.1–13.7). The TLRs obtained from $[^{68}\text{Ga}]^\text{Ga}$-PSMA-11 PET/CT varied between 1.6 and 10.9, with a mean TLR of 3.6 ± 2.1. For lesions located in
Among the newly diagnosed patients, there were 19 lesions with an SUV\textsubscript{max} of 11.2 ± 7.2 (range: 5.5–25.4) and an SUV\textsubscript{mean} of 5.3 ± 1.8 (range: 3.3–8.7); patients after TACE had 25 lesions, with an SUV\textsubscript{max} of 15.2 ± 6.6 (range: 3.4–29.3) and an SUV\textsubscript{mean} of 7.4 ± 2.7 (range: 3.8–13.7). The mean TLR obtained on \[^{68}\text{Ga}\]Ga-PSMA-11 PET/CT for newly diagnosed vs. after TACE was 3.2 ± 2.5 vs. 3.8 ± 1.9, respectively. There were no significant differences in the SUVs or TLRs between newly and previously diagnosed patients.

### Correlation between ceCT/MRI and \[^{68}\text{Ga}\]Ga-PSMA-11 PET/CT images

\[^{68}\text{Ga}\]Ga-PSMA-11 PET images were fused with the corresponding abdominal ceCT/MRI images using the semi-automatic image registration with manual adjustment for correct alignment. Visual interpretation of PET showed an increased accumulation of \[^{68}\text{Ga}\]Ga-PSMA-11 in the contrast-enhancing parts of the tumor visible on ceCT/MRI. Simultaneously, there was no observed uptake in the necrotic parts of the tumor.

\[^{68}\text{Ga}\]Ga-PSMA-11 PET/CT showed more lesions in the liver than ceCT/MRI (38 vs. 29; \(p = 0.007\)). The median size of the liver lesions on ceCT/MRI was 23 mm (range: 8–167 mm). Meanwhile, the median size of lesions not visible on ceCT/MRI but visualized on PET was 8 mm (range: 2–10 mm). Notably, two out of the 15 patients had unexpected extrahaepatic metastatic bone lesions on \[^{68}\text{Ga}\]Ga-PSMA-11 (Fig. 1).

Following abdominal imaging ceCT/MRI, all patients had initially qualified for surgical resection or TACE. Indeed, the results of \[^{68}\text{Ga}\]Ga-PSMA-11 PET/CT altered the previously planned treatment in five patients. In particular, due to additional foci revealed in the liver, two patients were disqualified from planned surgical resection, and one patient was disqualified from TACE. The remaining two patients were disqualified from surgery as \[^{68}\text{Ga}\]Ga-PSMA-11 revealed disseminated disease: one due to bone metastases (Fig. 1), and the second due to an 8-mm peritoneum metastasis (with an SUV\textsubscript{max} of 11.2), which was also found on ceCT but without contrast enhancement and deemed not related to cancer. All these patients were discussed at a multidisciplinary board meeting and finally qualified to chemotherapy.

### Compliance with tumor markers

Serum AFP positivity rate was 53% (8/15 patients) in the study group. The SUV\textsubscript{max} was 15.0 ± 5.4 (SUV\textsubscript{mean} 7.5 ± 2.6) in patients with a serum AFP level within the normal range, and 11.5 ± 8.5 (SUV\textsubscript{mean} 5.2 ± 1.4) in those with an elevated AFP level. Meanwhile, serum CA 19-9 results were positive in 20% of patients (3/15). The SUV\textsubscript{max} was 14.4 ± 7.0 (SUV\textsubscript{mean} 6.8 ± 2.6) in patients with a normal CA19-9 level, and 12.1 ± 3.8 (SUV\textsubscript{mean} 6.4 ± 2.1) in those with elevated CA 19-9 levels. Furthermore, 27% (4/15) of patients had a positive serum CEA measurement result. The SUV\textsubscript{max} was 14.5 ± 6.4 (SUV\textsubscript{mean} 7.1 ± 2.5) in patients with a normal CEA, and 10.4 ± 7.6 (SUV\textsubscript{mean} 4.4 ± 0.9) in those with an elevated CEA.

### Table 2

| Patient no. | SUV\textsubscript{max} of the tumor/metastasis | SUV\textsubscript{mean} of the tumor/metastasis | SUV\textsubscript{max} of the liver tissue | SUV\textsubscript{mean} of the liver tissue | TLR (SUV\textsubscript{max} of the tumor/ SUV\textsubscript{mean} of the liver) |
|-------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------|------------------------------------------|---------------------------------------------------------------|
| 1           | 16.3                                          | 5.7                                           | 6.7                                      | 4.5                                      | 3.6                                                            |
| 2           | 8.0                                           | 4.9                                           | 5.0                                      | 3.4                                      | 2.4                                                            |
| 3           | 29.3                                          | 6.7                                           | 3.2                                      | 2.7                                      | 10.9                                                           |
| 4           | 7.0                                           | 3.3                                           | 5.0                                      | 3.1                                      | 2.3                                                            |
| 5           | 17.6                                          | 7.5                                           | 5.6                                      | 4.4                                      | 4.0                                                            |
| 6           | 13.6                                          | 5.9                                           | 6.2                                      | 4.5                                      | 3.0                                                            |
| 7           | 7.5                                           | 5.6                                           | 5.6                                      | 4.4                                      | 1.9                                                            |
| 8           | 8.1                                           | 4.6                                           | 6.2                                      | 4.5                                      | 1.8                                                            |
| 9           | 25.4                                          | 5.5                                           | 4.8                                      | 3.3                                      | 7.7                                                            |
| 10          | 6.3                                           | 4.5                                           | 4.2                                      | 3.3                                      | 1.9                                                            |
| 11          | 5.5                                           | 3.8                                           | 4.2                                      | 3.3                                      | 1.7                                                            |
| 12          | 7.8                                           | 4.5                                           | 5.0                                      | 3.3                                      | 2.4                                                            |
| 13          | 6.8                                           | 4.7                                           | 5.0                                      | 3.3                                      | 2.1                                                            |
| 14          | 15.5                                          | 7.9                                           | 7.1                                      | 4.5                                      | 3.4                                                            |
| 15          | 17.8                                          | 8.5                                           | 6.3                                      | 3.4                                      | 5.2                                                            |
| 16          | 8.1                                           | 5.8                                           | 6.3                                      | 3.4                                      | 2.4                                                            |
| 17          | 7.4                                           | 4.5                                           | 6.3                                      | 3.4                                      | 2.2                                                            |
| 18          | 9.3                                           | 4.5                                           | 6.3                                      | 3.4                                      | 2.7                                                            |
| 19          | 12.0                                          | 8.0                                           | 6.3                                      | 3.4                                      | 3.5                                                            |
| 20          | 24.3                                          | 6.0                                           | 5.9                                      | 3.2                                      | 7.6                                                            |
| 21          | 11.4                                          | 4.4                                           | 5.0                                      | 3.1                                      | 3.7                                                            |
| 22          | 22.7                                          | 8.7                                           | 6.4                                      | 4.3                                      | 5.3                                                            |
| 23          | 9.6                                           | 5.4                                           | 6.4                                      | 4.3                                      | 2.2                                                            |
| 24          | 11.6                                          | 6.2                                           | 6.4                                      | 4.3                                      | 2.7                                                            |
| 25          | 19.6                                          | 10.3                                          | 6.4                                      | 4.3                                      | 4.6                                                            |
| 26          | 22.5                                          | 8.0                                           | 6.4                                      | 4.3                                      | 5.2                                                            |
| 27          | 18.2                                          | 9.6                                           | 6.4                                      | 4.3                                      | 4.2                                                            |
| 28          | 20.1                                          | 12.2                                          | 6.4                                      | 4.3                                      | 4.7                                                            |
| 29          | 17.3                                          | 6.0                                           | 6.4                                      | 4.3                                      | 4.0                                                            |
| 30          | 11.3                                          | 6.6                                           | 6.4                                      | 4.3                                      | 2.6                                                            |
| 31          | 20.6                                          | 12.4                                          | 6.4                                      | 4.3                                      | 4.8                                                            |
| 32          | 23.6                                          | 13.7                                          | 6.4                                      | 4.3                                      | 5.5                                                            |
| 33          | 16.9                                          | 8.3                                           | 6.4                                      | 4.3                                      | 3.9                                                            |
| 34          | 23.6                                          | 9.6                                           | 6.4                                      | 4.3                                      | 5.5                                                            |
| 35          | 12.1                                          | 8.4                                           | 6.4                                      | 4.3                                      | 2.8                                                            |
| 36          | 8.9                                           | 5.9                                           | 6.4                                      | 4.3                                      | 2.1                                                            |
| 37          | 12.7                                          | 7.2                                           | 6.1                                      | 3.9                                      | 3.3                                                            |
| 38          | 24.5                                          | 7.8                                           | 3.8                                      | 2.9                                      | 8.4                                                            |

SUV\textsubscript{max}, maximal standardized uptake value; SUV\textsubscript{mean}, mean standardized uptake value; TLR, tumor-to-liver ratio
level. No statistically significant relationships were found between the serum concentrations of AFP, CA 19-9, CEA, and PET parameters.

Histopathology and immunohistochemistry

All patients had histopathological confirmation of the diagnosis. Metastatic lesions in the bone and peritoneum were confirmed by clinical follow-up and imaging examinations. The use of \([^{68}\text{Ga}]\text{Ga-PSMA-11 PET/CT}\) did not show false-positive findings based on histopathology or follow-up.

Sample specimens for PSMA staining were available in six patients. The immunochemistry showed intense intra-tumoural microvessel staining for PSMA and no staining in epithelial tumor cells. There was visible intra-tumoural heterogeneity of the reaction in terms of intensity and distribution. A strong correlation between the histopathological pattern and PSMA expression was found. In trabecular patterns of HCC, the reaction was homogenously strong in vessels with a tendency to create hot spots. However, in pseudoglandular patterns of HCC, the reaction was weak; only a few vessels showed a slightly stronger reaction than in the sinusoids of the surrounding non-tumourous liver parenchyma. In a well-differentiated hepatocellular neoplasm with uncertain malignant potential (HUMP), no staining was identified in vessels, yet there was a positive reaction in the sinusoids that was stronger than in the non-tumourous liver tissue.

Additionally, in one patient with hepatitis B, there was a strong reaction for PSMA in intracellular hyaline bodies, and for PSMA, the reaction was weakly positive in the sinusoids in the surrounding non-tumourous liver parenchyma, but negative in the blood vessels and epithelial tumor cells.

Regardless of PSMA expression visible in the immunohistochemistry, the \([^{68}\text{Ga}]\text{Ga-PSMA-11 PET/CT}\) showed an increased uptake in all patients (Table 3). The examples of tracer uptake patterns and immunochemistry staining are shown in Figs. 2, 3, and 4.

Discussion

Because \([^{18}\text{F}]\text{F-choline PET/CT}\) examination is not available in our hospital and \([^{18}\text{F}]\text{FDG examination}\) is not reimbursed for HCC, another imaging method for HCC is required. \([^{68}\text{Ga}]\text{Ga-PSMA-11}\) was recently introduced for the PET/CT imaging of patients with prostate cancer, but incidental uptake has been described in other cancers, including reports on HCC \([12–18]\).

The present pilot study showed encouraging preliminary results confirming the clinical utility of \([^{68}\text{Ga}]\text{Ga-PSMA-11 PET/CT}\) in patients with HCC. All histopathologically proven cases of HCC showed an increased tracer uptake. The results of \([^{68}\text{Ga}]\text{Ga-PSMA-11 PET/CT}\) were compared with ceCT/MRI for a total of 44 lesions detected in 15 patients. However,
[68Ga]Ga-PSMA-11 PET/CT can be used for functional whole-body imaging, which may change their management. One of the most important findings is the clinical impact of the chosen imaging method on patient management. From a clinical point of view, the HCC treatment strategy includes surgery; local chemoembolization; and, in cases of disseminated disease, chemotherapy. [68Ga]Ga-PSMA-11 PET/CT results assisted the multidisciplinary team in choosing the optimal therapy. Functional and whole-body imaging PET revealed significantly more lesions than cCT/MRI, enforcing a crucial change in the treatment strategy in 33% of patients. These findings indicated the superiority of [68Ga]Ga-PSMA-11 PET/CT over conventional imaging modalities.

The use of [68Ga]Ga-PSMA-11 PET/CT in HCC has been evaluated in two prior studies [12, 13]. Kesler et al. [12] studied seven mostly newly diagnosed HCC patients, and

Table 3  [68Ga]Ga-PSMA-11 uptake and PSMA staining pattern on immunohistochemistry

| Number | Tumor (SUV<sub>max</sub>) | Tumor (SUV<sub>mean</sub>) | TLR | Pattern | PSMA staining |
|-------|--------------------------|---------------------------|-----|---------|---------------|
| 1     | 16.3                     | 5.7                       | 3.6 | Pseudoglandular | Weak reaction in few vessels |
| 2     | 7.0                      | 3.3                       | 2.3 | Trabecular | Strong reaction in vessels |
| 3     | 17.6                     | 7.5                       | 4.0 | Mix pseudoglandular and trabecular | Strong reaction in vessels in the trabecular pattern and a weak reaction in a few vessels in the pseudoglandular part |
| 4     | 15.5                     | 7.9                       | 3.4 | HUMP: well-differentiated hepatocellular neoplasm with uncertain malignant potential | No vessels staining, reaction in sinusoids (stronger than in the surrounding liver parenchyma) |
| 5     | 17.8                     | 8.5                       | 5.2 | Trabecular | Strong reaction in vessels |
| 6     | 11.4                     | 4.4                       | 3.7 | Mix pseudoglandular and trabecular | Strong reaction in vessels in the trabecular pattern and a weak reaction in a few vessels in the pseudoglandular part |

SUV<sub>max</sub>, maximal standardized uptake value; SUV<sub>mean</sub>, mean standardized uptake value; TLR, tumor-to-liver ratio.

Fig. 2  [68Ga]Ga-PSMA-11 PET/CT images of a 72-year-old man without a history of liver disease (patient no. 1). An ultrasound was performed due to abdominal pain, which revealed a huge (~100 mm) lesion in the liver suspicious of hemangioma. The MRI revealed a contrast-enhanced tumor with a suspicion of HCC or hemangioma. The laboratory tests for AFP, CEA, and CA19-9 were normal. The [68Ga]Ga-PSMA-11 PET/CT images showed high accumulation in the tumor with an SUV<sub>max</sub> of 16.3 and TLR of 3.6. a PET. b Fused axial PET/CT. c Maximum intensity projection image (MIP). Histopathology revealed hepatocellular carcinoma grade 2, with a pseudoglandular pattern. Immunohistochemistry showed d weak PSMA expression in the tumor-associated vasculature of HCC (×10) and e slightly stronger PMSA expression in some vessels than in the sinusoids of the surrounding healthy liver parenchyma (×20).
Kuyumcu et al. [13] included 19 patients with advanced disease. Both studies compared [68Ga]Ga-PSMA-11 with [18F]FDG. Kesler et al. [12] in newly diagnosed patients described more lesions revealed by [68Ga]Ga-PSMA-11 PET/CT than in [18F]FDG. Kuyumcu et al. [13] in patients with previously established diagnosis of HCC, so with a more advanced disease, showed that the utility of both tracers was comparable. In contrast, our cohort was more comprehensive, including patients with both types of disease status (i.e., those with a new diagnosis and a recurrence) and all had histopathological confirmation of disease. Importantly, patients with disease recurrence in our study had longer history of disease after TACE.

A previously published limited immunohistochemistry study showed that 74–80% of HCC tumors presented moderate-to-strong staining for PSMA, while completely negative staining was seen in only 4–26% of samples [11, 19]. All studies showed PSMA expression in the neovascular structures [11, 12, 19]. Tolkach et al. [19] also reported PSMA expression on the canalicular membrane within the liver, but no expression was detected in the vasculature of the surrounding normal liver tissue. Similarly, in our cohort, we confirmed that PSMA is specifically expressed in the tumor-associated vasculature.

Although one patient with hepatitis B showed also strong reaction for PSMA in the intracellular hyaline bodies, this was likely a nonspecific reaction. Additionally, a well-differentiated hepatocellular neoplasm with uncertain malignant potential showed no staining for PSMA in the vessels, but we observed bright, diffuse expression in the sinusoids. We also found a positive reaction in the vessels in both pseudoglandular and trabecular patterns of HCC, albeit of different intensity. The reaction was generally weak in pseudoglandular patterns of HCC, with slightly stronger spots demonstrated only in a few vessels. In contrast, it was homogeneously strong with a tendency to create hot spots in trabecular patterns of HCC. These differences have not yet been described in the literature. However, further studies with increased sample numbers are required to confirm observed dependency.

All HCC patients in our cohort had an increased uptake of [68Ga]Ga-PSMA-11, which is likely related to the abovementioned elevated PSMA expression in the intratumoral microvessels. Indeed, the observed tracer uptake in tumors was 3.6-fold higher than that in the surrounding liver, with the mean TLR for advanced and for newly diagnosed patients equaling 3.8 and 3.2, respectively. Other authors described a similar increase in tracer uptake in tumors compared...
with the surrounding liver; i.e., it was 3.3-fold higher in patients with advanced HCC and 3.8-fold higher in those who were newly diagnosed [12, 13].

Our semiquantitative analysis revealed a mean SUV max of 13.5, which is similar to that described by Kesler et al. for the enhanced part of the tumor in CT (i.e., an SUV max of 13.2; range: 9.5–15.4) [12]. However, the SUV max for HCC was higher in another cohort of patients with advanced disease (i.e., 17.4 ± 9; range 3.8–36.9) [13]. Nonetheless, we found no statistically significant difference in the uptake of [68Ga]Ga-PSMA-11 between newly diagnosed patients and those with recurrence after TACE.

Our findings, and those of others, suggest PSMA expression may be useful for therapeutic and diagnostic applications outside of prostate cancer. Indeed, Jiao et al. [11] reported that patients with HCC who had high vascular PSMA expression tend to have shorter overall survival. Therefore, [68Ga]Ga-PSMA-11 PET/CT could potentially be used as a prognostic factor in HCC [11]. The selective expression of PSMA in the tumor-associated vasculature in cases of HCC, and not in the tumor cells themselves, indicates PSMA may be an effective antiangiogenic treatment target for HCC [20–22]. In particular, the use of PSMA-targeted radioisotopes may be an effective HCC therapy. However, it has been suggested that the uptake of radiolabeled compounds by the microvascular endothelium (and not by tumor cells) may not be optimal (i.e., characterized by a quick washout). Despite this, recent pioneering dosimetry data of [177Lu]Lu-PSMA-617 treatment in other tumors with angiogenesis-associated PSMA expression (e.g., glioblastoma multiforme) has proven the possibility of such targeted treatment, without quick washout of radiolabeled compounds [23]. Moreover, in HCC, we found most extrahepatic metastatic sites (except bone) showed a higher uptake of tracer than the liver (with a TLR of 3.6 ± 2.1), indicating [177Lu]Lu-PSMA-617 may be a useful treatment. Indeed, according to the European Association of Nuclear Medicine (EANM) guideline based on the reported outrider phase II trial on [177Lu]Lu-PSMA-617, the required SUV max at dominant sites of tumor involvement should be at least 1.5-fold higher than the baseline SUV mean [68Ga]Ga-PSMA-11 of the liver for qualification for therapy [20, 21]. Therefore, the criterion of TLR > 1.5 used for the qualification of [177Lu]Lu-PSMA therapy would have been fulfilled by all patients in our cohort.

The current pilot study has major limitations to be disclosed. First, the number of patients is limited. The relatively small number of cases included is the result of strict inclusion criteria: only patients with histopathologically proven disease were qualified. The second limitation is the limited available sample tissue for immunohistochemistry staining.
Overall, we observed an increased uptake of $[^{68}\text{Ga}]$Ga-PSMA-11 in all patients with histopathologically proven HCC, and found a different model of PSMA staining in pseudoglandular pattern and trabecular patterns of HCC. However, these promising results need further evaluation to confirm the observed dependency. The important future task is to calculate sensitivity, specificity, and other validating measures of $[^{68}\text{Ga}]$Ga-PSMA-11 PET/CT in HCC. In particular, the performance characteristics of $[^{68}\text{Ga}]$Ga-PSMA-11 PET/CT in HCC should be assessed.

Conclusion

The use of $[^{68}\text{Ga}]$Ga-PSMA-11 PET/CT could detect PSMA expression in vivo in patients with histopathologically proven HCC. Therefore, $[^{68}\text{Ga}]$Ga-PSMA-11 PET/CT represents a potential novel imaging modality for patients with HCC. Immunochemistry confirmed the expression of PSMA in vitro in all patients with an increased uptake of $[^{68}\text{Ga}]$Ga-PSMA-11 on PET/CT. Moreover, the use of $[^{68}\text{Ga}]$Ga-PSMA-11 PET/CT resulted in a crucial change in the treatment in 33% of patients. Therefore, the potential role of $[^{68}\text{Ga}]$Ga-PSMA-11 PET/CT in patients with HCC should be evaluated in further studies.

Acknowledgments

We thank the patients who participated in the study, the Radiochemistry Group in the Department of Nuclear Medicine, the nursing staff, and the nuclear medicine technologists of the Medical University of Warsaw for their support. The authors acknowledge Proper Medical Writing Sp. z o.o. for editorial assistance.

Author’s contributions

Jolanta Kunikowska, Krzysztof Zieniewicz, and Leszek Królicki contributed to the study conception and design. Material preparation and data collection were performed by Jolanta Kunikowska, Leszek, Kraj, Bartosz Cieślak, Marcin Kotulska, and Waldemar Patkowski. Histopathological analysis was done by Beata Gere. Statistical analysis was done by Jolanta Kunikowska. The first draft of the manuscript was written by Jolanta Kunikowska, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Data availability

Raw data are available from the corresponding author on reasonable request.

Compliance with ethical standards

This article does not contain any studies with animals performed by any of the authors.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Ethics approval

This study was approved by the Ethical Committee of Medical University of Warsaw (KB/2/A/2018).

Consent to participate

Written informed consent was obtained from all patients.

Consent for publication

All authors gave their written consent for publication.

Conflict of interest

The authors declare that they have no conflict of interest.

Code availability (software application or custom code)

Calculations were performed on GraphPad PRISM 5 (GraphPad Software Inc.) and Excel for MAC (version 16.28, 2019 Microsoft).

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Villanueva A. Hepatocellular carcinoma. New England Journal of Medicine. 2019;380(15):1450–62. https://doi.org/10.1056/NEJMra1713263.
2. Tan CH, Low, S-CA, Thng CH. APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review. Int J Hepatol. 2011;2011:519783-. doi https://doi.org/10.4061/2011/519783.
3. Bertagna F, Bertoli M, Bosio G, Biasiotti G, Sadeghi R, Giubbini R, et al. Diagnostic role of radiolabeled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology International. 2014;8(4):493–500. https://doi.org/10.1007/s12072-014-9566-0.
4. Kunikowska J, Bartosz K, Leszek K. Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2018;45(5):886–7. https://doi.org/10.1007/s00259-018-3934-2.
5. Kunikowska J, Kuliniski R, Muylle K, Koziara H, Królicki L. 68Ga-prostate-specific membrane antigen-11 PET/CT: a new imaging option for recurrent glioblastoma multiforme? Clinical Nuclear Medicine. 2020;45(1).
6. Salas Fragomeni RA, Amir T, Sheikhbahaie S, Harvey SC, Javadi MS, Solnes LB, et al. Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms. J Nucl Med. 2018;59(6):371–7. https://doi.org/10.2967/jnumed.117.203570.
7. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical Cancer Research. 1997;3(1):81.
8. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhaprashu S, Goldsmith SJ, et al. Vascular targeted therapy with anti–prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. Journal of Clinical
Oncology. 2007;25(5):540–7. https://doi.org/10.1200/JCO.2006.07.8097.

9. Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer. Seminars in Nuclear Medicine. 2016;46(5):405–18. https://doi.org/10.1053/j.semnuclmed.2016.04.004.

10. Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, et al. (18)F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10:1):1–16. https://doi.org/10.7150/tnho.37894.

11. Jiao D, Li Y, Yang F, Han D, Wu J, Shi S, et al. Expression of prostate-specific membrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma. Clin Transl Gastroenterol. 2019. https://doi.org/10.14309/ctg.0000000000000041.

12. Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, et al. (68)Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med. 2018. https://doi.org/10.2967/jnumed.118.214833.

13. Kuyumcu S, Has-Simsek D, Iliaz R, Sanli Y, Buyukkaya F, Akyuz F, et al. Evidence of prostate-specific membrane antigen expression in hepatocellular carcinoma using 68Ga-PSMA PET/CT. Clin Nucl Med. 2019;44(9):702–6. https://doi.org/10.1097/RLU.0000000000002701.

14. Das J, Ray S, Tapadia R, Midha D, Mallick I. Prostate-specific membrane antigen-expressing hepatic lesion: metastatic or hepatocellular carcinoma. Indian J Nucl Med. 2020;35(1):58–60. https://doi.org/10.4103/ijnm.IJNM_145_19.

15. Patel D, Loh H, Le K, Stevanovic A, Mansberg R. Incidental detection of hepatocellular carcinoma on 68Ga-labeled prostate-specific membrane antigen PET/CT. Clinical Nuclear Medicine. 2017;42(11).

16. Taneja S, Taneja R, Kashyap V, Jha A, Jena A. 68Ga-PSMA uptake in hepatocellular carcinoma. Clinical Nuclear Medicine. 2017;42(1).

17. Soydal C, Alkan A, Ozkan E, Demirkazik A, Kucuk N. Ga-68 PSMA accumulation in hepatocellular carcinoma. Journal of Gastroenterology, Pancreatology & Liver Disorders. 2017;4:1. https://doi.org/10.15226/2374-815X/4/2/00180.

18. Sasikumar A, Joy A, Nanabala R, Pillai MRA, Thomas B, Vikraman KR. 68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2016;43(4):795–6. https://doi.org/10.1007/s00259-015-3297-x.

19. Tolkach Y, Goltz D, Kremer A, Ahmadzadehfar H, Bergheim D, Essler M, et al. Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging. Oncotarget. 2019;10(41):4149–60. https://doi.org/10.18632/oncotarget.27024.

20. Hofman MS, Vrieze C, Hekker RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–33. https://doi.org/10.1016/S1470-2045(18)30198-0.

21. Kratochwil C, Fendler W, Eiber M, Baum RP, Bozkurt M, Czermin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging. 2019;46. https://doi.org/10.1007/s00259-019-04485-3.

22. Mittlmeier LM, Unterrainer M, Todica A, Cyran CC, Rodler S, Bartenstein P, et al. PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(9):2216–7. https://doi.org/10.1007/s00259-019-04636-6.

23. Kunikowska J, Charzyńska I, Kulińska P, Pawlak R, Maurin M, Król B, et al. Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(6):1605–6. https://doi.org/10.1007/s00259-020-04715-z.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.